Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
- Conditions
- First Posted Date
- 2003-12-02
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 38
- Registration Number
- NCT00003388
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
🇺🇸Raritan Bay Medical Center, Perth Amboy, New Jersey, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Columbia University
- Registration Number
- NCT00002761
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 2078
- Registration Number
- NCT00002812
- Locations
- 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis
- Conditions
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2010-06-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00006367
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Illinois College of Medicine, Chicago, Illinois, United States
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00005962
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- First Posted Date
- 2003-10-28
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 640
- Registration Number
- NCT00003190
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
- Conditions
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00005998
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00070538
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2009-07-07
- Lead Sponsor
- Theradex
- Registration Number
- NCT00069966
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 350
- Registration Number
- NCT00070174
- Locations
- 🇺🇸
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸St. Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸All Children's Hospital, St. Petersburg, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.